ZOLMITRIPTAN 2.5MG TABLETS 6`S

Migraine Indicated for acute treatment of migraine with or without aura 2.5 mg PO/intranasally, initially, at onset of migraine Dosing considerations May increase dose to 5 mg; not to exceed 5 mg per single dose; individual response varies May repeat dose if migraine has not resolved after 2 hr; not to exceed 10 mg/24 hr Safety not established for tablets in the treatment of >3 migraines/30 days or >4 migraines/30 days for the intranasal formulation Adverse Effects 1-10% Dizziness (6-10%) Neck/throat/jaw pain (4-10%) Parasthesia (5-9%) Nausea (4-9%) Weakness (3-9%) Somnolence (5-8%) Warm/cold sensation (5-7%) Xerostomia (3-5%) Chest pain (2-4%) Diaphoresis (3%) Pain (2-3%) Dyspepsia (1-3%) Dysphagia (2%) Myasthenia (2%) Palpation (2%) Vertigo (2%) Hypoesthesia (1-2%) Myalgia (1-2%) <1% QT prolongation Bradycardia Tachycardia Thrombophlebitis Postural hypotension Hyperglycemia Alk phos increased Arthritis Twitching Myocardial infarction and artery vasospasm in patients with CAD risk factors

KES 8,512.00

(Inclusive of all taxes)